Pharmaceuticals, Biotechnology and Life Sciences
Amryt Pharma can now enrol young Epidermolysis Bullosa (EB) patients between the ages of 21 days to 4 years old to test AP101 as a potential treatment.
PledPharma has filed an application for an Orphan Drug Designation (ODD) to the US FDA for the its drug candidate which should reduce liver injury by paracetamol overdose, Aladote.
Takeda and TiGenix have presented new data from the Phase 3 ADMIRE-CD clinical trial of treatment refractory complex perianal fistulas in patients with Crohn’s disease at the 12th Congress of the European Crohn’s and Colitis Organisation (ECCO).
Catalyst Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, has announced…
Hansa Medical, a biopharmaceutical company focusing on novel immunomodulatory enzymes, has announced that the Committee for Orphan Medicinal Products (COMP)…
Amryt has received orphan drug designation from U.S. Food and Drug Administration (FDA) for its drug compound…
Horizon Pharma has announced that Ravicti (glycerol phenylbutyrate) Oral Liquid is now available in Canada through its affiliate….
Merck KGaA and Pfizer have announced that the US Food and Drug Administration (FDA) has granted avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Fast Track designation for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer.